New approaches to treatment in systemic vasculitis: Biological therapies

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 2, 2001, Pages 315-333

  Levine, Stuart M ^a   Stone, John H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biological; Cytotoxic T cell antigen 4 (CTLA 4); Interferon alpha; Interferon gamma; Interleukin 1; Interleukin 10; Interleukin 12; Tumour necrosis factor; Vasculitis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LENERCEPT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; PLACEBO; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR;

BEHCET DISEASE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; GIANT CELL ARTERITIS; HUMAN; IMMUNOTHERAPY; PATHOPHYSIOLOGY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 0034994597     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2000.0146     Document Type: Article

References (75)

1. Are animal models of vasculitis suitable tools?
2. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis
3. TNF neutralization in MS. Results of a randomized, placebo-controlled, multi-center study
4. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
5. A multi-center placebo-controlled study of methotrexate in giant cell arteritis
6. Update on the European Union Vasculitis Study Group
7. Etanercept in Wegener's granulomatosis (WG): Results of a six month trial to evaluate safety
8. A disease-specific activity index for Wegener's Granulomatosis: Modification of the Birmingham Vasculitis Activity Score
9. Etanercept in Wegener's granulomatosis (WG): Design of a randomized, multi-center trial
10. Phase I/II trial of etanercept in Wegener's granulomatosis: Safety and preliminary experience
11. IL-I inhibitors: Novel agents in the treatment of rheumatoid arthritis
12. Levels of synovial fluid interleukin-I receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils
13. Low levels of interleukin-I receptor antagonist coincide with kidney involvement in systemic lupus erythematosus
14. The role of the interleukin-I-receptor antagonist in blocking inflammation mediated by interleukin-I
15. Arterial inflammation in mice lacking the interleukin I receptor antagonist gene
16. Treatment of rheumatoid arthritis with recombinant human interleukin-I receptor antagonist
17. Treatment of interleukin-I receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients
18. Combining anti IL-I and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone
19. Combination benefit of treatment with recombinant human interleukin-I receptor antagonist (il-I ra) and pegylated recombinant human soluble tumor necrosis factor receptor type i (peg stnf-ri) in animal models of rheumatoid arthritis
20. IL-I beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: Relevance to systemic vasculitis
21. Induction of interleukin-I and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells
22. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-I alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis
23. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers
24. Combinations of low concentration of cytokines and acute agonists synergize in increasing the permeability of endothelial cell monolayers
25. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis
26. The pathogenesis of giant cell arteritis
27. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis
28. Platelet-derived growth factor, intimal hyperplasia and aschemic complications in giant cell arteritis
29. Disease patterns and tissue cytokine profiles in giant cell arteritis
30. Tissue destructive macrophages in giant cell arteritis
31. + T cells exhibiting an unbalanced ThI-Type T cell cytokine pattern: Reversal with IL-10
32. Cytokines profiles in Wegner's granulomatosis: Predominance of type I (ThI) in the granulomatous inflammation
33. + monocyte subpopulation in Kawasaki disease
34. Divergent cytokine production profile in Behcet's disease. Altered Th1/Th2 cell cytokine pattern
35. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis
36. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits
37. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand
38. ThI polarization of the immune response in Behcet's disease: A putative pathogenetic role of interleukin-12
39. Interleukin 10 treatment for rheumatoid arthritis
40. rHuIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study
41. Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis
42. Interleukin 10 gene transfer prevents experimental colitis in rats
43. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
44. Production of interleukin 6 by granulomas of giant cell arteritis
45. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions?
46. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis
47. Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: Relationship to systematic vasculitis and microvascular capillaroscopic abnormalities
48. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
49. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells
50. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels
51. Vasculitis in the Palmerston North mouse model of lupus: Phenotype and cytokine production profile of infiltrating cells
52. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras
53. Cytokines in experimental autoimmune vasculitis: Evidence for a Th2 type response
54. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis
55. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behcet's disease
56. Interferon-alpha treatment of Behcet's disease
57. Treatment of Adamantiades-Behcet disease with systemic interferon alfa
58. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: A randomised trial
59. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
60. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study
61. Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis
62. A dose ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group
63. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome
64. Long-term treatment of Churg-Strauss syndrome with interferon-alpha
65. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b
66. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy
67. Co-stimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
68. The Yin and Yang of T cell costimulation
69. CTLA-4 engagement inhibits IL-2 accumulation and cell progression upon activation of resting T cells
70. Differential T cell costimulatory requirement in CD28-deficient mice
71. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
72. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative role of CTLA-4
73. CTLA-4 is a second receptor for the B-cell activation antigen B7
74. CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris
75. Polymorphisms in CTLA-4 but not TNF-a or IL-1 genes are associated with Wegener's granulomatosis